Genocea Biosciences Inc. (GNCA) 12.48 $GNCA
Genocea Bio completes enrollment in pneumococcus vaccine trial
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 9:15AM CDT
GNCA: 12.48 (-0.23)
Genocea Completes Enrollment in Phase 2a Human Challenge Study of GEN-004 for the Prevention of Infection by Pneumococcus
Business Wire - Wed Apr 22, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported that it has completed enrollment in its Phase 2a human challenge study of GEN-004, Genocea's universal vaccine candidate for the prevention of infection by all serotypes of pneumococcus. The Company anticipates reporting top-line data from this study in the fourth quarter of 2015.
GNCA: 12.48 (-0.23)
Genocea to Present at the 14th Annual Needham & Co. Healthcare Conference
Business Wire - Wed Apr 08, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Jonathan Poole, chief financial officer, will present a company overview at the upcoming 14th Annual Needham & Co. Healthcare Conference. The presentation is scheduled for Wednesday, April 15, 2015 at 9:20 a.m. EDT in New York, NY.
GNCA: 12.48 (-0.23)
Genocea Biosciences (GNCA) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:48AM CDT
Genocea Biosciences saw a big move last session, as the company’s shares fell by over 5% on the day.This reverses the recent trend for GNCA as the stock is now up 32% since Mar 11.
LCI: 66.45 (-0.28), GNCA: 12.48 (-0.23)
Clinical Trial Patients' Positive Experiences Bode Well For Genocea's Billion Dollar HSV Drug
Probio Invest - at Seeking Alpha - Mon Mar 30, 12:17PM CDT
JNJ: 100.43 (+0.13), GNCA: 12.48 (-0.23), GSK: 46.57 (-0.67)
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:21AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 5% on the day.
EARS: 4.65 (-0.75), GNCA: 12.48 (-0.23)
InsiderInsights.com Daily Round Up 3/17/15: NMFC, JMP, RGS, MLNK
InsiderInsights - at Seeking Alpha - Wed Mar 18, 9:55AM CDT
EGLE: 8.55 (+0.05), NMFC: 15.00 (+0.23), WYN: 90.73 (+0.50), ADMS: 17.62 (-0.21), FMD: 6.56 (+0.01), LNG: 78.61 (+1.61), MLNK: 3.75 (unch), GNCA: 12.48 (-0.23), GOOG: 539.36 (+5.39), WSTC: 32.53 (-0.23), EVER: 18.50 (+0.03), LCI: 66.45 (-0.28), JMP: 7.99 (+0.09), LII: 107.70 (+2.09), NERV: 5.68 (+0.05), MHK: 182.02 (+2.39), PF: 41.01 (-0.40), RGS: 17.40 (+0.01), EPD: 33.35 (-0.29)
Genocea Bio and Bovie Med close equity offerings
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 10:15AM CDT
BVX: 3.25 (+0.40), GNCA: 12.48 (-0.23)
Genocea Biosciences, Inc. Announces Closing of $51.7 Million Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Business Wire - Tue Mar 17, 9:41AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 818,181 shares of common stock, at the public offering price of $8.25 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Genocea to 6,272,726 shares and increased the total gross proceeds raised in this offering to $51.7 million, before deducting the underwriting discounts and commissions. The net proceeds to Genocea from this offering were approximately $48.4 million.
GNCA: 12.48 (-0.23)
3 Health Care Stocks Under $10 to Trade for Breakouts
at The Street - Thu Mar 12, 12:35PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
NRX: 8.00 (-0.27), GNCA: 12.48 (-0.23), AXN: 1.77 (+0.01)
Genocea Bio prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 8:17AM CDT
GNCA: 12.48 (-0.23)
Genocea Biosciences, Inc. Announces Pricing of $45 Million Public Offering
Business Wire - Thu Mar 12, 7:54AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the pricing of its public offering of 5,454,545 shares of its common stock at a public offering price of $8.25 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 818,181 shares of common stock at the same price. The offering is expected to close on or about March 17, 2015, subject to satisfaction of customary closing conditions.
GNCA: 12.48 (-0.23)
Genocea Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:14PM CDT
GNCA: 12.48 (-0.23)
Genocea Biosciences, Inc. Commences Public Offering of Common Stock
Business Wire - Wed Mar 11, 3:01PM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. As part of this proposed offering, Genocea intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All the shares in the offering will be sold by Genocea.
GNCA: 12.48 (-0.23)
Genocea elects Michael Higgins to board
M2 - Mon Mar 02, 5:35AM CST
Biopharmaceutical company Genocea Biosciences (NasdaqGMLGNCA) disclosed on Friday the addition of Michael Higgins to its board of directors.
GNCA: 12.48 (-0.23)
Recent Developments at Pharma Companies: Special Research on Discovery Labs, Enzon, Fate Therapeutics, Genetic Technologies, and Genocea Biosciences
PR Newswire - Mon Feb 16, 7:20AM CST
Editor Note: For more information about this release, please scroll to bottom.
GENE: 4.88 (-0.05), FATE: 6.29 (-0.10), ENZN: 1.70 (+0.20), GNCA: 12.48 (-0.23), DSCO: 1.25 (unch)
Genocea Biosciences' (GNCA) CEO Chip Clark on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 11:12AM CST
GNCA: 12.48 (-0.23)
Genocea Biosciences misses by $0.11
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:11AM CST
GNCA: 12.48 (-0.23)
Genocea Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Thu Feb 12, 7:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2014.
GNCA: 12.48 (-0.23)
Genocea to Host Fourth Quarter and Year End 2014 Financial Results Conference Call & Webcast on February 12, 2015
Business Wire - Thu Feb 05, 8:30AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on February 12, 2015 at 9:00 a.m. ET to discuss financial results for the fourth quarter and year end 2014. The presentation, hosted by Genocea President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the company's recent progress and upcoming milestones.
GNCA: 12.48 (-0.23)
Genocea Bio completes enrollment in pneumococcus vaccine trial
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 9:15AM CDT
GNCA: 12.48 (-0.23)
Genocea Completes Enrollment in Phase 2a Human Challenge Study of GEN-004 for the Prevention of Infection by Pneumococcus
Business Wire - Wed Apr 22, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported that it has completed enrollment in its Phase 2a human challenge study of GEN-004, Genocea's universal vaccine candidate for the prevention of infection by all serotypes of pneumococcus. The Company anticipates reporting top-line data from this study in the fourth quarter of 2015.
GNCA: 12.48 (-0.23)
Genocea to Present at the 14th Annual Needham & Co. Healthcare Conference
Business Wire - Wed Apr 08, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Jonathan Poole, chief financial officer, will present a company overview at the upcoming 14th Annual Needham & Co. Healthcare Conference. The presentation is scheduled for Wednesday, April 15, 2015 at 9:20 a.m. EDT in New York, NY.
GNCA: 12.48 (-0.23)
Genocea Biosciences (GNCA) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:48AM CDT
Genocea Biosciences saw a big move last session, as the company’s shares fell by over 5% on the day.This reverses the recent trend for GNCA as the stock is now up 32% since Mar 11.
LCI: 66.45 (-0.28), GNCA: 12.48 (-0.23)
Clinical Trial Patients' Positive Experiences Bode Well For Genocea's Billion Dollar HSV Drug
Probio Invest - at Seeking Alpha - Mon Mar 30, 12:17PM CDT
JNJ: 100.43 (+0.13), GNCA: 12.48 (-0.23), GSK: 46.57 (-0.67)
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:21AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 5% on the day.
EARS: 4.65 (-0.75), GNCA: 12.48 (-0.23)
InsiderInsights.com Daily Round Up 3/17/15: NMFC, JMP, RGS, MLNK
InsiderInsights - at Seeking Alpha - Wed Mar 18, 9:55AM CDT
EGLE: 8.55 (+0.05), NMFC: 15.00 (+0.23), WYN: 90.73 (+0.50), ADMS: 17.62 (-0.21), FMD: 6.56 (+0.01), LNG: 78.61 (+1.61), MLNK: 3.75 (unch), GNCA: 12.48 (-0.23), GOOG: 539.36 (+5.39), WSTC: 32.53 (-0.23), EVER: 18.50 (+0.03), LCI: 66.45 (-0.28), JMP: 7.99 (+0.09), LII: 107.70 (+2.09), NERV: 5.68 (+0.05), MHK: 182.02 (+2.39), PF: 41.01 (-0.40), RGS: 17.40 (+0.01), EPD: 33.35 (-0.29)
Genocea Bio and Bovie Med close equity offerings
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 10:15AM CDT
BVX: 3.25 (+0.40), GNCA: 12.48 (-0.23)
Genocea Biosciences, Inc. Announces Closing of $51.7 Million Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Business Wire - Tue Mar 17, 9:41AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 818,181 shares of common stock, at the public offering price of $8.25 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Genocea to 6,272,726 shares and increased the total gross proceeds raised in this offering to $51.7 million, before deducting the underwriting discounts and commissions. The net proceeds to Genocea from this offering were approximately $48.4 million.
GNCA: 12.48 (-0.23)
3 Health Care Stocks Under $10 to Trade for Breakouts
at The Street - Thu Mar 12, 12:35PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
NRX: 8.00 (-0.27), GNCA: 12.48 (-0.23), AXN: 1.77 (+0.01)
Genocea Bio prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 8:17AM CDT
GNCA: 12.48 (-0.23)
Genocea Biosciences, Inc. Announces Pricing of $45 Million Public Offering
Business Wire - Thu Mar 12, 7:54AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the pricing of its public offering of 5,454,545 shares of its common stock at a public offering price of $8.25 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 818,181 shares of common stock at the same price. The offering is expected to close on or about March 17, 2015, subject to satisfaction of customary closing conditions.
GNCA: 12.48 (-0.23)
Genocea Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:14PM CDT
GNCA: 12.48 (-0.23)
Genocea Biosciences, Inc. Commences Public Offering of Common Stock
Business Wire - Wed Mar 11, 3:01PM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. As part of this proposed offering, Genocea intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All the shares in the offering will be sold by Genocea.
GNCA: 12.48 (-0.23)
Genocea elects Michael Higgins to board
M2 - Mon Mar 02, 5:35AM CST
Biopharmaceutical company Genocea Biosciences (NasdaqGMLGNCA) disclosed on Friday the addition of Michael Higgins to its board of directors.
GNCA: 12.48 (-0.23)
Recent Developments at Pharma Companies: Special Research on Discovery Labs, Enzon, Fate Therapeutics, Genetic Technologies, and Genocea Biosciences
PR Newswire - Mon Feb 16, 7:20AM CST
Editor Note: For more information about this release, please scroll to bottom.
GENE: 4.88 (-0.05), FATE: 6.29 (-0.10), ENZN: 1.70 (+0.20), GNCA: 12.48 (-0.23), DSCO: 1.25 (unch)
Genocea Biosciences' (GNCA) CEO Chip Clark on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 11:12AM CST
GNCA: 12.48 (-0.23)
Genocea Biosciences misses by $0.11
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:11AM CST
GNCA: 12.48 (-0.23)
Genocea Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Thu Feb 12, 7:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2014.
GNCA: 12.48 (-0.23)
Genocea to Host Fourth Quarter and Year End 2014 Financial Results Conference Call & Webcast on February 12, 2015
Business Wire - Thu Feb 05, 8:30AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on February 12, 2015 at 9:00 a.m. ET to discuss financial results for the fourth quarter and year end 2014. The presentation, hosted by Genocea President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the company's recent progress and upcoming milestones.
GNCA: 12.48 (-0.23)
